UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2006
SUNESIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
| 000-51531 |
| 94-3295878 |
(State or Other Jurisdiction |
| (Commission |
| (IRS Employer |
of Incorporation) |
| File Number) |
| Identification No.) |
|
|
|
|
|
341 Oyster Point Boulevard |
|
| ||
South San Francisco, California |
| 94080 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (650) 266-3500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On June 29, 2006, Sunesis Pharmaceuticals, Inc., publicly disseminated a press release announcing that David C. Stump, M.D., and Homer L. Pearce, Ph.D., have been appointed as a Class I member and a Class II member, respectively, of its Board of Directors.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated June 29, 2006.
* * * * * * * * *
2
SIGNATURE(S)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUNESIS PHARMACEUTICALS, INC. | |||
|
|
|
|
|
Date: July 5, 2006 |
|
|
|
|
|
| By: |
| /s/ DARYL B. WINTER, PH.D. |
|
|
|
| Daryl B. Winter, Ph.D. |
|
|
|
| Senior Vice President, General Counsel |
Exhibit No. |
| Description |
|
|
EX-99.1 |
| Press Release dated June 29, 2006 |